182 related articles for article (PubMed ID: 22920637)
1. The pathogenesis of acute kidney impairment in patients with multiple myeloma.
Batuman V
Adv Chronic Kidney Dis; 2012 Sep; 19(5):282-6. PubMed ID: 22920637
[TBL] [Abstract][Full Text] [Related]
2. Proximal tubular injury in myeloma.
Batuman V
Contrib Nephrol; 2007; 153():87-104. PubMed ID: 17075225
[TBL] [Abstract][Full Text] [Related]
3. The role of immunological assessment in patients with acute kidney injury and possible myeloma.
Lachmann HJ; Wassef NL
Adv Chronic Kidney Dis; 2012 Sep; 19(5):287-90. PubMed ID: 22920638
[TBL] [Abstract][Full Text] [Related]
4. Serum free light chain measurement aids the diagnosis of myeloma in patients with severe renal failure.
Hutchison CA; Plant T; Drayson M; Cockwell P; Kountouri M; Basnayake K; Harding S; Bradwell AR; Mead G
BMC Nephrol; 2008 Sep; 9():11. PubMed ID: 18808676
[TBL] [Abstract][Full Text] [Related]
5. Cytotoxicity of myeloma light chains in cultured human kidney proximal tubule cells.
Pote A; Zwizinski C; Simon EE; Meleg-Smith S; Batuman V
Am J Kidney Dis; 2000 Oct; 36(4):735-44. PubMed ID: 11007675
[TBL] [Abstract][Full Text] [Related]
6. Treatment of acute kidney injury with cast nephropathy.
Walther C; Podoll AS; Finkel KW
Clin Nephrol; 2014 Jul; 82(1):1-6. PubMed ID: 24725380
[TBL] [Abstract][Full Text] [Related]
7. Renoprotection by pituitary adenylate cyclase-activating polypeptide in multiple myeloma and other kidney diseases.
Li M; Maderdrut JL; Lertora JJ; Arimura A; Batuman V
Regul Pept; 2008 Jan; 145(1-3):24-32. PubMed ID: 17935800
[TBL] [Abstract][Full Text] [Related]
8. Myeloma kidney: toward its prevention--with new insights from in vitro and in vivo models of renal injury.
Sengul S; Li M; Batuman V
J Nephrol; 2009; 22(1):17-28. PubMed ID: 19229815
[TBL] [Abstract][Full Text] [Related]
9. A monoclonal V kappa l light chain responsible for incomplete proximal tubulopathy.
Decourt C; Bridoux F; Touchard G; Cogné M
Am J Kidney Dis; 2003 Feb; 41(2):497-504. PubMed ID: 12552516
[TBL] [Abstract][Full Text] [Related]
10. The Proximal Tubule Toxicity of Immunoglobulin Light Chains.
Sirac C; Batuman V; Sanders PW
Kidney Int Rep; 2021 May; 6(5):1225-1231. PubMed ID: 34013100
[TBL] [Abstract][Full Text] [Related]
11. Management options for cast nephropathy in multiple myeloma.
Cockwell P; Hutchison CA
Curr Opin Nephrol Hypertens; 2010 Nov; 19(6):550-5. PubMed ID: 20827195
[TBL] [Abstract][Full Text] [Related]
12. Immunoglobulin free light chain levels and recovery from myeloma kidney on treatment with chemotherapy and high cut-off haemodialysis.
Hutchison CA; Heyne N; Airia P; Schindler R; Zickler D; Cook M; Cockwell P; Grima D
Nephrol Dial Transplant; 2012 Oct; 27(10):3823-8. PubMed ID: 22273664
[TBL] [Abstract][Full Text] [Related]
13. Pituitary adenylate cyclase-activating polypeptide is a potent inhibitor of the growth of light chain-secreting human multiple myeloma cells.
Li M; Cortez S; Nakamachi T; Batuman V; Arimura A
Cancer Res; 2006 Sep; 66(17):8796-803. PubMed ID: 16951196
[TBL] [Abstract][Full Text] [Related]
14. Light chains removal by extracorporeal techniques in acute kidney injury due to multiple myeloma: a position statement of the Onconephrology Work Group of the Italian Society of Nephrology.
Fabbrini P; Finkel K; Gallieni M; Capasso G; Cavo M; Santoro A; Pasquali S
J Nephrol; 2016 Dec; 29(6):735-746. PubMed ID: 27757797
[TBL] [Abstract][Full Text] [Related]
15. Myeloma kidney with isolated tubulointerstitial light chain deposition in a renal allograft.
Balamuthusamy S; Hamrahian M; Zhang R; Batuman V
Clin Transplant; 2009; 23(6):848-52. PubMed ID: 19210683
[TBL] [Abstract][Full Text] [Related]
16. Efficient removal of immunoglobulin free light chains by hemodialysis for multiple myeloma: in vitro and in vivo studies.
Hutchison CA; Cockwell P; Reid S; Chandler K; Mead GP; Harrison J; Hattersley J; Evans ND; Chappell MJ; Cook M; Goehl H; Storr M; Bradwell AR
J Am Soc Nephrol; 2007 Mar; 18(3):886-95. PubMed ID: 17229909
[TBL] [Abstract][Full Text] [Related]
17. Plasmapheresis in cast nephropathy: yes or no?
Madore F
Curr Opin Nephrol Hypertens; 2015 Mar; 24(2):177-82. PubMed ID: 25590785
[TBL] [Abstract][Full Text] [Related]
18. Myeloma kidney: advances in molecular mechanisms of acute kidney injury open novel therapeutic opportunities.
Davenport A; Merlini G
Nephrol Dial Transplant; 2012 Oct; 27(10):3713-8. PubMed ID: 23114897
[TBL] [Abstract][Full Text] [Related]
19. The evolving use of serum free light chain assays in haematology.
Pratt G
Br J Haematol; 2008 May; 141(4):413-22. PubMed ID: 18318757
[TBL] [Abstract][Full Text] [Related]
20. Light Chain Cast Nephropathy: Practical Considerations in the Management of Myeloma Kidney-What We Know and What the Future May Hold.
Manohar S; Nasr SH; Leung N
Curr Hematol Malig Rep; 2018 Jun; 13(3):220-226. PubMed ID: 29725932
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
